Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 590

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 3
Chunk 590
---
 -   -   -   (9,289)  -   (9,289)Other comprehensive income  -   -   -   -   51   51 Balance, December 31, 2023  3,189  $3  $52,262  $(40,310) $(203) $11,752                          Issuance of common shares  92   -   112   -   -   112 Stock based compensation  -   -   818   -   -   818 Net loss for the period  -   -   -   (9,826)  -   (9,826)Other comprehensive income  -   -   -   -   1   1 Balance, December 31, 2024  3,281  $3  $53,192  $(50,136) $(202) $2,857 

The accompanying notes are an integral part of these audited consolidated financial statements.

 F-5Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Cash Flows

(In thousands)

   Year ended     December 31,    2024  2023        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(9,826) $(9,289)Adjustments to reconcile net loss to net cash used in operating activities:        Stock-based compensation  818   1,020 Net change in fair value of trading marketable securities  (282)  (641)Non-cash lease expense  33   40 Changes in operating assets and liabilities:        Prepaid expenses and other current assets  457   430 Accounts payable and accrued liabilities  449   296 Accounts payable - related parties  31   (23)Fixed cash payments related to operating leases  (30)  (40)Net cash used in operating activities  (8,350)  (8,207)         CASH FLOWS FROM INVESTING ACTIVITIES        Investment in trading marketable securities  (481)  (13,685)Proceeds from disposition